Ascletis Pharma (HKSE:01672) 3-Year EBITDA Growth Rate : 14.80% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Ascletis Pharma 3-Year EBITDA Growth Rate?

Ascletis Pharma's EBITDA per Share for the six months ended in Dec. 2023 was HK$-0.12.

During the past 3 years, the average EBITDA Per Share Growth Rate was 14.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -60.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Ascletis Pharma was 14.80% per year. The lowest was -166.40% per year. And the median was -47.10% per year.

Competitive Comparison of Ascletis Pharma's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Ascletis Pharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascletis Pharma's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascletis Pharma's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Ascletis Pharma's 3-Year EBITDA Growth Rate falls into.

Ascletis Pharma 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Ascletis Pharma (HKSE:01672) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Ascletis Pharma 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Ascletis Pharma's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascletis Pharma (HKSE:01672) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascletis Pharma Inc (HKSE:01672) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ASCLF:USA

Address

198 Qidi Road, 12th Floor, Building D, HIPARK, Xiaoshan District, Zhejiang Province, Hangzhou, CHN, 311200

Website

https://www.ascletis.com

Ascletis Pharma Inc is an investment holding company engaged in the research and development, production, marketing, and sale of pharmaceutical products. It has three marketed products, i.e. ritonavir tablets, GANOVO, and ASCLEVIR. Geographically, it operates in Mainland China and other countries.

Ascletis Pharma (HKSE:01672) Headlines

No Headlines